Readystate Asset Management LP Boosts Stock Holdings in Janux Therapeutics, Inc. $JANX

Readystate Asset Management LP lifted its position in Janux Therapeutics, Inc. (NASDAQ:JANX) by 38.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 960,379 shares of the company’s stock after purchasing an additional 264,423 shares during the period. Janux Therapeutics comprises about 1.0% of Readystate Asset Management LP’s portfolio, making the stock its 23rd biggest holding. Readystate Asset Management LP owned about 1.60% of Janux Therapeutics worth $23,472,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the company. California State Teachers Retirement System increased its holdings in Janux Therapeutics by 1.1% in the second quarter. California State Teachers Retirement System now owns 37,139 shares of the company’s stock valued at $858,000 after buying an additional 404 shares in the last quarter. ProShare Advisors LLC grew its position in shares of Janux Therapeutics by 8.1% during the 2nd quarter. ProShare Advisors LLC now owns 10,284 shares of the company’s stock valued at $238,000 after acquiring an additional 771 shares during the period. Ameritas Investment Partners Inc. increased its stake in shares of Janux Therapeutics by 25.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock valued at $93,000 after purchasing an additional 820 shares in the last quarter. Virtus Investment Advisers LLC raised its holdings in Janux Therapeutics by 37.9% in the 2nd quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock worth $85,000 after purchasing an additional 1,011 shares during the period. Finally, DNB Asset Management AS raised its holdings in Janux Therapeutics by 19.2% in the 2nd quarter. DNB Asset Management AS now owns 9,253 shares of the company’s stock worth $214,000 after purchasing an additional 1,488 shares during the period. 75.39% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Charles M. Winter sold 2,401 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $13.73, for a total value of $32,965.73. Following the completion of the sale, the insider directly owned 77,721 shares in the company, valued at $1,067,109.33. This represents a 3.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO David Alan Campbell sold 8,072 shares of the stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $13.73, for a total value of $110,828.56. Following the completion of the sale, the chief executive officer directly owned 284,982 shares of the company’s stock, valued at approximately $3,912,802.86. This represents a 2.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 22,366 shares of company stock valued at $371,245 in the last ninety days. 29.40% of the stock is currently owned by corporate insiders.

Janux Therapeutics Stock Up 0.5%

Shares of JANX opened at $13.21 on Wednesday. Janux Therapeutics, Inc. has a 52-week low of $12.12 and a 52-week high of $38.42. The firm’s fifty day moving average is $13.93 and its two-hundred day moving average is $21.27. The stock has a market cap of $794.58 million, a PE ratio of -7.86 and a beta of 2.88.

Analyst Upgrades and Downgrades

Several brokerages have commented on JANX. Wedbush reissued an “outperform” rating and issued a $45.00 price objective (down from $76.00) on shares of Janux Therapeutics in a report on Tuesday, December 2nd. Clear Str lowered Janux Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 20th. Piper Sandler cut their price target on shares of Janux Therapeutics from $42.00 to $30.00 and set an “overweight” rating for the company in a report on Friday, January 16th. Bank of America reduced their price objective on shares of Janux Therapeutics from $58.00 to $49.00 and set a “buy” rating for the company in a research report on Tuesday, December 2nd. Finally, Stifel Nicolaus dropped their target price on shares of Janux Therapeutics from $46.00 to $38.00 and set a “buy” rating on the stock in a research report on Tuesday, December 2nd. Eleven research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Janux Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.08.

Janux Therapeutics Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.